Cooley M&A

JANUARY 22, 2025

Portfolio optimization through divestitures of noncore assets In addition to pharmas smaller appetite in 2024, pharma companies continued to slim down by shedding nonessential assets to sharpen their strategic focus on core products. 2] Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Cooley M&A

JANUARY 23, 2024

Strategic innovation Strategic acquirers are feeling more pressure to consummate bolt-on acquisitions in order to round out their portfolios, enter new markets and fill innovation gaps. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. billion.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52